Jean Mah

Dr. Jean Mah

Principal Applicant

Pediatrics and Clinical Neurosciences Professor at the Cumming School of Medicine

Pediatric Neurologist and the Director of the Pediatric Neuromuscular Program at the Alberta Children’s Hospital


NMD4C Involvement: Pillar 2: Clinical Research, Theme 5: Open Science

Academic web profile

Biography

Dr. Jean Mah is a pediatric neurologist and the director of the Pediatric Neuromuscular Program at the Alberta Children’s Hospital in Calgary, Alberta, Canada. She is a Professor of Pediatrics and Clinical Neurosciences at the Cumming School of Medicine, University of Calgary.  She is currently involved in multicenter clinical research studies related to pediatric neuromuscular diseases.  


Recent Publications

Mah, JK. Therapeutic options for Duchenne muscular dystrophy: hope or hype?. Ther Adv Neurol Disord. 2025.18 17562864251346326 PMID:40547866

Gauvreau, G, Behlim, T, Ng, P, Hodgkinson, V, Selby, K, Mah, JK et al.. Respiratory and Bulbar Support in Spinal Muscular Atrophy Type I Treated with Nusinersen. Can J Neurol Sci. 2025. 1-8 PMID:40357918

Tsampalieros, A, McKim, D, Barrowman, N, Bijelic, V, Mah, JK, McMillan, HJ et al.. Lung Volume Recruitment and Quality of Life in Duchenne Muscular Dystrophy: Secondary Analysis of the STEADFAST Randomized Controlled Trial. Ann Am Thorac Soc. 2025. PMID:40185084

Qian, C, Klimchak, AC, Szabo, SM, Gooch, KL, Dragan, R, Prior, HJ et al.. Longitudinal Outcomes Among Patients With Duchenne Muscular Dystrophy: A Canadian Retrospective Population-Based Study. Muscle Nerve. 2025.71 (6)955-962 PMID:39945205

McMillan, HJ, Gonorazky, H, Campbell, C, Chrestian, N, Crone, M, Dowling, JJ et al.. Equitable Access to Disease-Modifying Therapies for Canadian Children with SMA and Four SMN2 Copies. Can J Neurol Sci. 2024. 1-3 PMID:39534980

Mercuri, E, Vilchez, JJ, Boespflug-Tanguy, O, Zaidman, CM, Mah, JK, Goemans, N et al.. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024.23 (4)393-403 PMID:38508835

Dang, UJ, Damsker, JM, Guglieri, M, Clemens, PR, Perlman, SJ, Smith, EC et al.. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial. Neurology. 2024.102 (5)e208112 PMID:38335499

Price, TR, Hodgkinson, V, Westbury, G, Korngut, L, Innes, MA, Marshall, CR et al.. A Study on the Incidence and Prevalence of 5q Spinal Muscular Atrophy in Canada Using Multiple Data Sources. Can J Neurol Sci. 2024.51 (5)660-671 PMID:38178730

Niri, F, Nicholls, J, Baptista Wyatt, K, Walker, C, Price, T, Kelln, R et al.. Alberta Spinal Muscular Atrophy Newborn Screening-Results from Year 1 Pilot Project. Int J Neonatal Screen. 2023.9 (3) PMID:37606479

Clemens, PR, Rao, VK, Connolly, AM, Harper, AD, Mah, JK, McDonald, CM et al.. Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study. J Neuromuscul Dis. 2023.10 (3)439-447 PMID:37005891

See more on PubMed